GC Medical Science (142280) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, GC Medical Science (142280) reported revenue of 108.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025108.4 billion KRW2.9 billion KRW3.5 billion KRW[source]
2024103.9 billion KRW2.3 billion KRW3.4 billion KRW[source]
202394.0 billion KRW1.8 billion KRW1.9 billion KRW[source]
2022113.1 billion KRW-1.3 billion KRW-3.1 billion KRW[source]
2021101.7 billion KRW-20.2 billion KRW-21.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202584.0 billion KRW40.7 billion KRW43.4 billion KRW[source]
202480.8 billion KRW40.9 billion KRW39.9 billion KRW[source]
202385.7 billion KRW52.8 billion KRW32.9 billion KRW[source]
202289.8 billion KRW58.2 billion KRW31.7 billion KRW[source]
202191.5 billion KRW56.1 billion KRW35.4 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20257.2 billion KRW-4.0 billion KRW-3.5 billion KRW[source]
20243.7 billion KRW-3.3 billion KRW-5.5 billion KRW[source]
20234.2 billion KRW-3.8 billion KRW-3.4 billion KRW[source]
202210.9 billion KRW-5.7 billion KRW1.8 billion KRW[source]
2021-18.2 billion KRW-3.3 billion KRW18.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice